Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Post by mercedesmanon Feb 23, 2022 12:15pm
193 Views
Post# 34454175

Theory

TheoryBased on my theory that the SP will roughly track the Tigris enrollment, it would appear thta we were up to 40 patients, briefly, but that 7 have dropped out of the Trial.

Not to worry though as with clearing ICU's all across the US I see enrollment moving to 8 or 10 per month soon.

Using the low side of the estimate, that could put us near 65 enrollees by the start of summer.

DIMI?

per recent release 

"Based on the approved protocol amendment, we are now progressing to the site contracting phase, which we expect will provide greater visibility on the revised DIMI trial timeline.

My theory here is that we will add a penny per DIMI Trial enrollee as well.

So if we add 20 DIMI Trial enrollees by start of summer, the SP should be .65 + .20 = .85  (157% upside based on today's price)...but still wildly conservative in relation to Paradigm's latest.

(debated about using 2 cents per enrollee based on DIMI being a "when not IF, approval",  and $ 2B valuations for lesser competitor pumps, but decided to take a more conservative approach)

That's my theory, and I'm sticking to it.   Based on science.  With a 95% margin of error.


MM 


<< Previous
Bullboard Posts
Next >>